


ONCOLOGY UNDER THE MICROSCOPE


As the prevalence of cancer continues to rise, the need for innovative and cutting-edge treatments becomes increasingly important. This infographic explores the intricacies of the oncology market, assessing its impact on patients, its global market share and the new drugs to watch in the oncology space

THE ONCOLOGY MARKET

Oncology revenue and market share (2019-2025)



Top ten oncology drugs by revenue (2022)



Future oncology blockbusters

Teclistamab

Company: Janssen


Usage: Multiple myeloma

Launch: 2022 - US and Europe

Expected launch: 2024 - Japan

Forecasted annual sales in G7 markets: \$1.8bn in 2031

Probability of success for teclistamab in Japan for multiple myeloma:



Capivasertib

Company: AstraZeneca

Usage: Breast cancer

Expected launch: 2024 - US, Europe and Japan


Forecasted annual sales in G7 markets: \$1bn+ in 2031

Probability of success for capivasertib in the US for metastatic breast cancer:




THE HUMAN IMPACT OF CANCER

Most common cancers by region (2020)



PROJECTED NUMBER OF PEOPLE LIVING WITH CANCER IN THE UK (2022)



According to Macmillan, average cancer survival in the UK is now estimated to be over 10 years from diagnosis, up from a median of one year in the 1970s and six years in 2007.

Source: Macmillan, 2022